Pacgen Life Science Corporation (TSX-V: PBS) completed a non-brokered private placement of 12,300,000 units at $0.06 per unit for gross proceeds of $738,000.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) intends to complete a non-brokered private placement of 1,000,000 units at a price of $0.30 per unit for gross proceeds of $300,000
APAC Resources Inc. (CSE: APG) and XORTX Pharma Corp. completed reverse take-over and acquisition by APAC of XORTX. Resulting company, XORTX Therapeutics Inc., to trade on CSE
ESSA Pharma Inc. (TSX-V: EPI; NASDAQ: EPIX) closed an initial US $20,325,000 brokered equity offering and concurrent US $675,000 non-brokered private placement for aggregate gross proceeds of US $21 million.
Abattis Bioceuticals Corp. (CSE: ATT; OTC: ATTBF) closed second and final tranche of non-brokered private placement, issuing 6,310,048 units at $0.43 per unit for gross proceeds of $2,713,321.
Burcon NutraScience Corporation (TSX: BU; NASDAQ: BUR) intend to close a rights offering of up to 9,456,793 common shares at $0.57 per share for gross proceeds of up to $5,390,372.01
H-Source Holdings Ltd. (TSX-V: HSI; OTCQB: HSCHF) completed private placement offering of 17,250,000 common shares at $0.10 for gross proceeds of $1,725,000. Mackie Research Capital Corporation led the offering
SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF) closed non-brokered private placement of 31,061,300 units at $0.15 per unit for gross proceeds of $4.65 million.
BlueOcean NutraSciences Inc. (TSX-V: BOC) closed second and final tranche of non-brokered private placement, issuing 1,875,000 units for gross proceeds of $150,000.